|
Dr. Labaudinière is President and CEO of FoldRx Pharmaceuticals, Inc., bringing over 19 years of international experience in drug discovery and development, including 16 years in multinational pharmaceutical companies, such as Glaxo, RPR and Aventis. Prior to FoldRx, Dr. Labaudinière was Senior Vice-President of Research and Development at Genome Therapeutics, now Oscient Pharmaceuticals. At Genome Therapeutics, he was responsible for building and directing all drug discovery and development activities. He oversaw the development of Genome Therapeutics' lead product candidate, Ramoplanin, for the prevention, treatment and control of serious hospital-based infections and Genome Therapeutics' biopharmaceutical portfolio of discovery and development alliances with pharmaceutical companies including Amgen, AstraZeneca, bioMérieux, Schering-Plough and Wyeth, in the field of osteoporosis, asthma and infectious diseases.
Before joining GenomeTherapeutics, Dr. Labaudinière held numerous senior management positions at Glaxo, RPR and Aventis, having full oversight for discovery and development programs, in many different therapeutic areas, from target selection to drug candidate selection and clinical development programs. His R&D efforts have resulted in several therapeutics reaching clinical development and the market.
Dr. Labaudinière is a graduate of Ecole Nationale Supérieure De Chimie in Montpellier, France and is author of over 70 publications and patents.
| 